$1.36
+0.01 (+0.74%)
BTMD News12 articles
PDS Biotech Surges 60% Despite Heavy Dilution from $11.3M Financing
PDSB shares surged 60% after a $11.3M PIPE financing, but the deal adds 40M share equivalents, diluting existing holders by over 70%.
PDS Biotech Soars 36% on $22.55M Financing: Dilution Concerns Loom
PDS Biotechnology (PDSB) surged 36% after announcing a $22.55 million PIPE led by Nant Capital, but the deal involves significant dilution. Here's the breakdown.
PDS Biotech Diverts All New Equity Cash to Lender Amid Funding Crunch
PDS Biotech's lender now takes 100% of net cash from new equity deals outside its ATM until a $6M promissory note is repaid, worsening an already tight funding situation.
Danaher Plunges 11% as Biotech Growth Disappoints, Triggering Valuation Reset
Danaher shares dropped 11% after its biotech segment underperformed expectations, leading to a valuation adjustment. Full-year core growth guidance was narrowed to 3%-4%.
Danaher Tumbles 11% as Biotech Growth Disappoints, Triggering Valuation Reset
Danaher shares plunged 11% on Tuesday after biotech growth fell short of expectations, prompting a sharp valuation reset even as quarterly revenue and earnings topped forecasts.
Biotech Sector Hit by $15B Loss as Vertex, Ionis Stumble
Vertex and Ionis shares slumped after setbacks, erasing $14.8B in market cap. Crinetics, BridgeBio, and Vera gained $6.1B combined.
Recursion Pharmaceuticals Rallies as Short Interest and Russell Flows Drive AI-Biotech Surge
Recursion Pharmaceuticals (RXRX) rose 4.7% to $3.98, driven by heavy short interest and Russell index flows. The stock's volume surged above average as the market focused on upcoming clinical catalysts.
Recursion Pharma Rallies Past Biotech ETFs; Insider Sales and Cash Position in Focus
Recursion Pharmaceuticals (RXRX) surged 8% in a four-session week, beating biotech ETFs. Filings show insider sales, while the company's $665M cash position and upcoming data updates remain key.
Legend Biotech Surges 42% on Promising Early CAR-T Data
Legend Biotech shares surged 42% after early Phase 1 data showed all six high-dose patients with relapsed B-cell non-Hodgkin lymphoma responded to its in vivo CAR-T therapy, with five achieving complete responses.
Legend Biotech Surges on Promising Early In Vivo CAR-T Data
Legend Biotech shares soared over 35% after early Phase 1 data showed all six high-dose patients with relapsed/refractory B-cell NHL responded to its in vivo CAR-T drug LB2501, with five complete responses and no relapses as of April 1.
HCW Biologics Rockets 122% as Traders Flock to Micro-Cap Biotech
HCW Biologics shares skyrocketed 122% to $2.35 on Wednesday as traders piled into the micro-cap biotech, fueled by a new stock offering and first-quarter revenue of $6.54 million from a licensing deal.
Edesa Biotech Surges 54% on Renewed ARDS Drug Optimism
Edesa Biotech (EDSA) shares surged 54% on Monday, driven by renewed interest in February data showing paridiprubart reduced 28-day ARDS mortality to 24% from 33%.